Sub-acute and acute toxicity of *Ferula asafoetida* and *Silybum marianum* formulation and effect of the formulation on delaying gastric emptying

Ramanaiah Illuri¹, Sudeep Heggar Venkataramana¹*, David Daguet² and Shyamprasad Kodimule¹

Abstract

Background: Delayed gastric emptying play an important role in the pathology of functional dyspepsia. Owing to their functional attributes in alleviating the gastrointestinal disorders, single or polyherbal formulations have gained attention to treat the symptoms of functional dyspepsia. We have investigated the safety and efficacy of a novel formulation of *Ferula asafoetida* oleo resin and standardized *Silybum marianum* extract (Asdamarin).

Methods: The effect of asdamarin on delayed gastric emptying was investigated in Sprague Dawley rats using phenol red method. The acute and sub-acute oral toxicity was evaluated in wistar rats following OECD guidelines 425 and 407 respectively. The data were analyzed by one-way ANOVA using GraphPad Prism 5.0 software.

Results: Oral administration of Asdamarin dose-dependently improved the delay in gastric emptying as evident from the significant increase in the gastrointestinal transit time (*p* < 0.001). The LD50 of asdamarin was estimated to be more than 2000 mg/kg. Further, in the 28-day sub-acute toxicity study, the administration of 250, 500 and 1000 mg/kg of Asdamarin did not significantly altered the feed and water consumption, body weight change, biochemical and haematological parameters compared to control animals. Macroscopic and histopathological examination of vital organs revealed no toxic signs.

Conclusion: The preliminary data from the present study provides the first evidence on the possible effectiveness of novel formulation of *F. Asafoetida* and *S. marianum* extracts in alleviating the associated symptoms of functional dyspepsia. The toxicity data indicated that Asdamarin can be considered safe up to 1000 mg/kg dose.

Keywords: Herbal formulation, Dyspepsia, Safety, Rats

Background

Dyspepsia is an umbrella term used to characterize abdominal pain centered in the epigastrium, sometimes combined with other gastrointestinal complaints. Functional dyspepsia is a common gastrointestinal disorder associated with decrement in the quality of life [1]. FD is characterized majorly by the disturbances in the gastric emptying and motility [2]. There is accumulating evidence that distinct subgroups of uninvestigated dyspepsia exist in the general population, suggesting the requirement for separate evaluation and treatment strategies [3, 4]. Treatments for FD include acid suppressing medicines (proton pump inhibitors), Selective Serotonin re-uptake inhibitors (SSRIs) and drugs affecting gastric motility such as domperidone and mosapride [5]. Medicinal plant preparations have gained increasing attention in the treatment of FD due to their potential health benefits and safety [5–7]. Most of the herbal remedies for treating FD symptoms worldwide are combinations of several medicinal plants [8].

*Ferula asafoetida* belonging to the family *Umbelliferae* is a perennial plant valued for its oleo-gum-resin (exudates obtained from the rhizome) used in traditional...
Herbs (P) Ltd. supplied by the Department of Quality Control, Vidya The investigational herbal formulation, Asdamarin was designed to evaluate the efficacy of Asdamarin in improving the delayed gastric emptying, and to investigate it’s in vivo toxicity.

Methods
Asdamarin
The investigational herbal formulation, Asdamarin was supplied by the Department of Quality Control, Vidya Herbs (P) Ltd.

High performance liquid chromatography (HPLC) analysis
The HPLC analysis was performed on a C18 column (4.6 × 150 mm, Phenomenex Kinetex) at a UV detection of 288 nm (HPLC-LC 2010HT). The mobile phase of methanol/0.5% phosphoric acid/water was flowed at 1.0 mL/min through the column.

Chemicals and animals
Phenol red powder were purchased from Sigma (St. Louis, MO). Wistar rats (6–8 weeks) and male Sprague Dawley (SD) rats (190–200 g) were procured from authorized suppliers of laboratory animals – Biogen, Bangalore, India (Reg No. 971/PO/RcBiBt/S/2006/CPCSEA). The animals were placed in polypropylene cages and housed in a room under controlled atmosphere (temperature, 22 ± 3 °C, humidity, 30–70%; 12 h light/dark cycle). During a 1-week acclimatization period, all rats consumed a commercial diet and tap water ad libitum. The animal studies were performed after due clearance from the Institutional Animal Ethics Committee (VHPL/PCL/IAEC/05/18) independently formed by CPCSEA (Committee for the purpose of control and supervision of experiments on animals, a statutory committee established under the Prevention of Cruelty to Animals Act, 1960 in India).

Determination of gastric emptying by phenol red method
Twenty-four male SD rats were divided into four groups of six animals each. Group I was control group administered with physiological saline; Group II animals were given physiological saline for seven days and on the 8th day reference drug Domiperidone was administered. Group III and IV were administered orally with two test doses of Asdamarin (50 and 100 mg/kg) for seven days. On day 8, 2 h later to the respective treatments gastric emptying was measured using phenol red method as described previously [1]. 18-h fasted rats were administered intragastrically with 1.5% carboxymethyl cellulose sodium salt containing 0.05% phenol red (0.5 mL/mouse). Rats were sacrificed after 20 min by ketamine/xylazine (80 mg/kg 2/10 mg/kg 1) overdose. Stomach was harvested, and gastric content collected. The gastric content was treated with 10 mL of 0.1 M NaHCO3 and centrifuged at 3000 rpm for 15 min. The amount of phenol red in the supernatant was determined based on the absorbance at 570 nm measured using a microplate reader (Multiskan EX, Thermo Scientific). The amount of phenol red from an animal sacrificed immediately after the above-mentioned administration procedure was used as the standard sample. Gastric emptying was calculated using the formula: (1-amount of phenol red in the test sample/amount of phenol red in the standard sample) × 100. Percentage of gastrointestinal transit time (GIT) was

Methods
Asdamarin
The investigational herbal formulation, Asdamarin was supplied by the Department of Quality Control, Vidya Herbs (P) Ltd.
determined using the formula: (Total length of small intestine of rat/Length of phenol red movement in the intestine) × 100.

**Acute oral toxicity of Asdamarin**

Asdamarin was evaluated for acute oral toxicity at the dose level of 2000 mg kg⁻¹ in accordance with OECD (Organization for Economic Cooperation and Development) guideline 425 [23]. Five female wistar rats were housed in a cage prior to dosing. A limit test was performed where the first animal was administered orally with the upper limit dose of 2000 mg kg⁻¹ b.w. and observed for 24 h. Depending upon the survival, other four animals were given the limit dose and observed for mortality. The animals were observed individually after dosing once during the first 30 min, periodically during the first 24 h, with special attention given during the first 4 h, and daily thereafter for a total of 14 days.

**Sub-acute oral toxicity**

Fifty (25 male and 25 female) healthy wistar rats aged 6–8 weeks were used for evaluating the sub-acute oral toxicity of Asdamarin. The study was performed in compliance with OECD guideline No. 407 [24]. The animals were divided into five groups of 10 animals each (5 males and 5 females). Group I animals received 0.9% normal saline (control), group II, III and IV received 250, 500 and 1000 mg kg⁻¹ asdamarin on daily basis for 28 days. In order to monitor reverse sign of any toxicity a satellite group was included as group V. This group was administered with 1000 mg kg⁻¹ Asdamarin daily for 28 days, and there was no further treatment for 14 days before the end of study. Visual observations for mortality, behavioural pattern and clinical signs of illness were made daily during the study period. Body weight of animals in each group was assessed on weekly intervals and, feed and water consumption were assessed daily for the entire period. At the end of study, overnight fasted rats were anesthetized by ketamine/xylazine.

![Fig. 1 HPLC chromatogram of (a) Silibinin (98%) and (b) Asdamarin](image-url)
Table 1: Effect of Asdamarin on mean feed consumption (g) in rats

| Sex | Day | Control   | 250 mg/kg | 500 mg/kg | 1000 mg/kg | 1000 mg/kg reversal |
|-----|-----|-----------|-----------|-----------|------------|---------------------|
| Male| 7   | 17.83 ± 0.95 | 16.8 ± 0.42 | 18.31 ± 0.7 | 18.19 ± 0.61 | 21.7 ± 0.86         |
|     | 14  | 18.8 ± 0.36  | 17.72 ± 0.93 | 22.13 ± 0.7 | 20.12 ± 0.58 | 24.36 ± 0.47        |
|     | 21  | 20.84 ± 0.46 | 19.3 ± 0.24  | 24.64 ± 0.57| 21.44 ± 0.72 | 23.92 ± 0.14        |
|     | 28  | 21.54 ± 1.03 | 20.09 ± 0.47 | 24.03 ± 0.54| 22.81 ± 0.69 | 23.3 ± 0.66         |
|     | 35  | –          | –          | –          | –           | 19.78 ± 0.29        |
|     | 42  | –          | –          | –          | –           | 23.95 ± 0.35        |
| Female| 7   | 14.62 ± 0.30 | 14.18 ± 0.46 | 13.86 ± 0.35 | 12.61 ± 0.90 | 14.00 ± 0.82        |
|     | 14  | 15.83 ± 0.57 | 16.43 ± 0.48 | 15.15 ± 0.33 | 17.17 ± 0.34 | 16.90 ± 1.27        |
|     | 21  | 15.77 ± 0.87 | 15.81 ± 0.33 | 15.11 ± 0.54 | 17.12 ± 0.30 | 17.63 ± 0.28        |
|     | 28  | 16.35 ± 0.68 | 17.74 ± 0.68 | 17.22 ± 0.39 | 18.89 ± 0.52 | 19.63 ± 1.11        |
|     | 35  | –          | –          | –          | –           | 20.69 ± 0.49        |
|     | 42  | –          | –          | –          | –           | 18.88 ± 1.08        |

Values are expressed as mean ± s.e.m. (n = 10 for each group). Data were analyzed by one-way ANOVA. *p < 0.05 were considered as statistically significant compared to control.

**Fig. 2** Effect of Asdamarin on (a) gastric emptying and (b) percentage gastrointestinal transit time (GIT) in SD rats. Values are expressed as mean ± SEM (n = 6). Data were analyzed by one way ANOVA followed by Dunnett’s t test. ***p < 0.001 compared to control group.
(80 mg·kg⁻¹/10 mg·kg⁻¹) overdose. Blood samples of the animals were collected via cardiac puncture in tubes containing ethylenediaminetetraacetic acid (EDTA) and tested for haematological and biochemical parameters. The organs were excised, and relative weights of vital organs were determined using the formula, 100 × (organ weight/body weight).

Major organs such as liver, kidneys, brain, spleen and heart were preserved in 10% buffered formalin for histological examination. The tissue samples were fixed in 4% formalin, dehydrated with a graded alcohol series, embedded in paraffin, and then cut into 5 μm thickness. The sections were stained with hematoxylin and eosin (H&E, Sigma Aldrich, St. Louis, MO, USA). The images were captured using a microscope (Leica, Germany).

Statistical analysis
The data were analyzed using GraphPad Prism version 5.0. The values were recorded as mean ± s.e.m. and analyzed statistically using one-way ANOVA followed by Tukey test. *p < 0.05 was considered statistically significant.

Results
HPLC analysis of Asdamarin
Asdamarin was characterized for the presence of silymarin (not less than 25%). It contains combination of flavonoids such as Silybin A, Silybin B, Taxifolin, Silychristin, Silydianin, Isosilybin A and Isosilybin B (Fig. 1).

---

**Table 2** Effect of Asdamarin on average water consumption (mL) in rats

| Sex   | Day | Control        | 250 mg/kg       | 500 mg/kg       | 1000 mg/kg     | 1000 mg/kg reversal |
|-------|-----|----------------|-----------------|-----------------|----------------|---------------------|
| Male  | 7   | 28.46 ± 0.94   | 27.49 ± 0.99    | 35.71 ± 1.08    | 30.8 ± 1.15    | 36.63 ± 1.81        |
|       | 14  | 34.46 ± 1.35   | 32.46 ± 3.27    | 39.54 ± 2.68    | 36.51 ± 0.96   | 38.57 ± 2.43        |
|       | 21  | 35.46 ± 2.50   | 30.57 ± 1.10    | 44.74 ± 0.65    | 41.69 ± 1.53   | 39.06 ± 1.14        |
|       | 28  | 30.69 ± 1.46   | 32.74 ± 1.49    | 30.14 ± 0.55    | 42.8 ± 1.72    | 38.66 ± 1.79        |
|       | 35  | -              | -               | -               | -              | 37.09 ± 2.27        |
|       | 42  | -              | -               | -               | -              | 36.94 ± 1.05        |
| Female| 7   | 30.51 ± 1.14   | 25.77 ± 1.19    | 26.46 ± 2.84    | 29.29 ± 1.31   | 27.63 ± 3.13        |
|       | 14  | 29.6 ± 29.69   | 24.4 ± 28.03    | 28.8 ± 30.11    | 33.2 ± 35.4    | 28.00 ± 29.09       |
|       | 21  | 32.00 ± 29.89  | 27.00 ± 24.17   | 27.6 ± 25.60    | 35.00 ± 34.17  | 36.2 ± 30.14        |
|       | 28  | 32.83 ± 2.83   | 36.8 ± 2.43     | 35.94 ± 1.91    | 38.26 ± 2.20   | 37.11 ± 2.06        |
|       | 35  | -              | -               | -               | -              | 40.31 ± 3.37        |
|       | 42  | -              | -               | -               | -              | 27.17 ± 2.13        |

Values are expressed as mean ± s.e.m. (n = 10 for each group). Data were analyzed by one-way Anova. *p < 0.05 were considered as statistically significant compared to control.
Effect of Asdamarin on gastric emptying

The percentage gastric emptying was assessed after 20 min of phenol red meal administration in rats. The gastric emptying was lower in control animals (64.94%) while the animals in Domperidone treated group showed an increase in percentage of gastric emptying (78.86%). Rats treated with 50 and 100 mg/kg doses of Asdamarin exhibited increased percentage of gastric emptying (69.8 and 74.79% respectively) as compared to control (Fig. 2a). However, the data were not statistically significant.

Further, in the present study gastrointestinal transit (GIT) was found to be increasing significantly in the extract and standard drug treated rats as compared to control. The GIT was 55.19% in control group. There was a significant increase in GIT among the animals treated with single dose of Domperidone \( (p < 0.001) \). Asdamarin administered rats showed significant improvement in the GIT dose dependently \( (p < 0.001) \). The GIT was 68.9 and 70.28% respectively for 50 and 100 mg/kg Asdamarin (Fig. 2b).

Acute oral toxicity

In the present study, single dose administration of Asdamarin \( (p.o.) \) in female rats at 2000 mg/kg did not induce any changes in the behavioural, motor and neuronal functions. Asdamarin treatment had no effect on mortality, body weight change or gross observation. Hence, the lethal dose of Asdamarin might be higher than 2000 mg/kg.

Sub-acute oral toxicity

Body weight, food and water consumption

28-day oral administration of Asdamarin did not alter the feed and water consumption in rats compared to the respective control animals (Tables 1 and 2). Further

### Table 3 Relative organ weights of rats treated with Asdamarin for 28 days

| Sex  | Organ | Control | Asdamarin (mg/kg, B.W) |
|------|-------|---------|------------------------|
|      |       |         | 250 mg/kg | 500 mg/kg | 1000 mg/kg | 1000 R mg/kg |
|      |       |         |           | 1000 mg/kg | 1000 mg/kg | 1000 mg/kg |
| Male | Brain | 0.808 ± 0.05 | 0.795 ± 0.03 | 0.659 ± 0.006* | 0.714 ± 0.042 | 0.686 ± 0.014 |
|      | Heart | 0.368 ± 0.03 | 0.337 ± 0.01 | 0.308 ± 0.006 | 0.326 ± 0.016 | 0.303 ± 0.004 |
|      | Liver | 3.613 ± 0.14 | 3.360 ± 0.13 | 3.511 ± 0.126 | 3.815 ± 0.126 | 2.456 ± 0.047 |
|      | Spleen| 0.486 ± 0.09 | 0.44 ± 0.02 | 0.399 ± 0.036 | 0.447 ± 0.04 | 0.392 ± 0.03 |
|      | Kidneys| 0.339 ± 0.01 | 0.335 ± 0.02 | 0.308 ± 0.019 | 0.341 ± 0.015 | 0.284 ± 0.009 |
| Female| Brain | 0.930 ± 0.033 | 0.858 ± 0.022 | 0.914 ± 0.028 | 0.913 ± 0.019 | 0.874 ± 0.032 |
|      | Heart | 0.403 ± 0.026 | 0.388 ± 0.021 | 0.385 ± 0.0187 | 0.396 ± 0.007 | 0.336 ± 0.013 |
|      | Liver | 3.349 ± 0.331 | 3.199 ± 0.150 | 3.054 ± 0.228 | 3.150 ± 0.089 | 2.627 ± 0.084 |
|      | Spleen| 0.520 ± 0.061 | 0.465 ± 0.076 | 0.448 ± 0.036 | 0.523 ± 0.045 | 0.325 ± 0.026 |
|      | Kidneys| 0.503 ± 0.025 | 0.515 ± 0.015 | 0.505 ± 0.022 | 0.521 ± 0.008 | 0.455 ± 0.024 |

Values are expressed as mean ± s.e.m. \((n = 10\) for each group). \(*p < 0.05\) were considered significant using one-way Anova. * denote significant difference compared to control.
there was neither mortality nor significant changes in the body weights of rats treated with 250–1000 mg/kg Asdamarin in comparison with control group (Figs. 3 and 4). Physical observations indicated no toxic signs in the fur, skin, eyes, tremors, salivation and behavioural patterns of rats at the tested doses. No abnormal gross findings were observed in the necropsies of Asdamarin treated rats at all the test doses. Overall, no adverse events were recorded during the toxicity evaluation of Asdamarin.

**Relative organ weights**
The results of relative organ weight measurement are shown in Table 3. The 28-day treatment with Asdamarin did not significantly alter the relative organ weights of male and female rats compared to the control group.

**Haematology and clinical biochemistry analysis**
The effect of 28-day treatment with Asdamarin on haematological parameters is presented in Table 4. Except for the marginal changes in some of the parameters, the haematological assessment showed no significant change in the treatment groups as compared to control. Further, Asdamarin administration exerted no significant changes in the biochemical analyses such as renal (urea and creatinine) and liver function (alanine aminotransferase, aspartate aminotransferase and

### Table 4 Effect of Asdamarin on haematological parameters in rats

| Unit          | Control         | Asdamarin (mg/kg, BW) |
|---------------|-----------------|-----------------------|
|               |                 | 250                   | 500       | 1000       | 1000 Reversal |
| **Male**      |                 |                       |           |            |              |
| Haemoglobin g/dL | 16.78 ± 0.56    | 17.60 ± 0.27          | 15.40 ± 0.66 | 16.06 ± 0.56 | 16.26 ± 0.51 |
| RBC 10^6/μL  | 9.848 ± 1.25    | 8.55 ± 0.15           | 7.72 ± 0.24 | 7.97 ± 0.3  | 7.97 ± 0.27  |
| HCT %         | 43.98 ± 0.66    | 45.66 ± 0.53          | 40.40 ± 1.08 | 41.24 ± 1.84 | 41.00 ± 1.26 |
| MCV fL        | 51.98 ± 1.03    | 53.54 ± 1.16          | 52.48 ± 1.33 | 51.80 ± 0.85 | 51.52 ± 0.82 |
| MCH Pg        | 19.74 ± 0.39    | 20.56 ± 0.41          | 19.86 ± 0.3  | 20.12 ± 0.20 | 20.34 ± 0.32 |
| MCHC g/dL     | 38.10 ± 1.06    | 38.50 ± 0.22          | 38.04 ± 1.06 | 38.96 ± 0.43 | 39.60 ± 0.35 |
| Platelets 10^3/μL | 270.6 ± 21.78  | 307.4 ± 16.85         | 313.0 ± 16.88 | 313.6 ± 10.16 | 311.4 ± 20.48 |
| WBC 10^3/μL  | 22.06 ± 0.87    | 19.22 ± 3.12          | 19.46 ± 1.29 | 19.62 ± 2.76 | 20.04 ± 2.11 |
| Lymphocytes % | 90.92 ± 1.66    | 88.74 ± 0.88          | 93.84 ± 0.62 | 93.94 ± 0.76 | 90.20 ± 1.47 |
| Monocytes %   | 3.18 ± 0.41     | 3.42 ± 0.19           | 3.25 ± 0.16  | 2.27 ± 0.14  | 2.97 ± 0.30  |
| Neutrophils % | 4.54 ± 1.08     | 6.38 ± 0.7            | 2.80 ± 0.41  | 2.82 ± 0.56  | 5.56 ± 1.08  |
| Eosinophils % | 1.33 ± 0.17     | 1.43 ± 0.07           | 0.99 ± 0.07  | 0.95 ± 0.06  | 1.25 ± 0.12  |
| Basophils %   | 0.06 ± 0.02     | 0.06 ± 0.02           | 0.06 ± 0.02  | 0.06 ± 0.02  | 0.06 ± 0.02  |
| Clotting time Seconds | 33.0 ± 14.59 | 32.60 ± 4.49          | 39.80 ± 21.67 | 25.00 ± 6.50 | 27.40 ± 5.97 |
| **Female**    |                 |                       |           |            |              |
| Haemoglobin g/dL | 16.68 ± 0.57    | 15.48 ± 0.30          | 16.64 ± 0.466 | 15.50 ± 0.59 | 15.42 ± 0.34 |
| RBC 10^3/μL  | 7.57 ± 0.26     | 7.67 ± 0.21           | 7.13 ± 0.24  | 6.93 ± 0.62  | 7.45 ± 0.10  |
| HCT %         | 43.98 ± 1.66    | 39.22 ± 0.53          | 38.78 ± 1.03 | 36.84 ± 3.15 | 39.36 ± 0.72 |
| MCV fL        | 58.14 ± 1.22    | 54.28 ± 1.18          | 56.74 ± 0.83 | 60.32 ± 1.09 | 56.90 ± 0.33 |
| MCH Pg        | 22.00 ± 0.29    | 20.16 ± 0.39          | 20.48 ± 0.31 | 21.38 ± 1.59 | 20.64 ± 0.27 |
| MCHC g/dL     | 37.90 ± 0.36    | 39.42 ± 0.26          | 39.74 ± 0.31 | 40.18 ± 2.81 | 39.14 ± 0.35 |
| Platelets 10^3/μL | 310.8 ± 40.08  | 345.2 ± 12.87         | 300.0 ± 28.68 | 338.8 ± 41.25 | 272.8 ± 18.13 |
| WBC 10^3/μL  | 11.02 ± 1.71    | 8.28 ± 1.25           | 8.40 ± 1.38  | 9.36 ± 1.53  | 9.36 ± 1.58  |
| Lymphocytes % | 91.28 ± 1.66    | 94.30 ± 0.24          | 94.64 ± 0.79 | 93.04 ± 0.58 | 92.18 ± 1.82 |
| Monocytes %   | 2.954 ± 0.52    | 2.18 ± 0.11           | 2.19 ± 0.34  | 2.016 ± 0.24 | 2.70 ± 0.52  |
| Neutrophils % | 4.50 ± 0.97     | 2.58 ± 0.12           | 3.22 ± 0.33  | 3.08 ± 0.28  | 3.96 ± 1.21  |
| Eosinophils % | 1.25 ± 0.22     | 0.92 ± 0.04           | 0.92 ± 0.15  | 0.85 ± 0.10  | 1.13 ± 0.21  |
| Basophils %   | 0.06 ± 0.02     | 0.06 ± 0.02           | 0.06 ± 0.02  | 0.06 ± 0.02  | 0.06 ± 0.02  |
| Clotting time Seconds | 64.2 ± 19.90 | 33.0 ± 5.46           | 26.40 ± 3.09 | 39.00 ± 11.79 | 53.80 ± 14.61 |

Values are expressed as mean ± s.e.m. (n = 10 for each group). *p < 0.05 were considered significant using one-way Anova
alkaline phosphatase) parameters, total protein and albumin (Table 5).

**Histopathology**

The histopathological examination of vital organs showed no toxic signs. The treatment with 1000 mg kg\(^{-1}\) did not induce any changes in the cellular architecture of the examined tissues of male and female rats. Figures 5 and 6 shows the normal tissue morphology and absence of any gross lesions in organs.

**Table 5 Effect of Asdamarin on serum biochemical parameters in rats**

| Unit        | Control | Asdamarin (mg/kg) |
|-------------|---------|-------------------|
|             |         | 250               | 500 | 1000 | 1000 Reversal |
| Male        |         |                   |     |      |               |
| ALT IU/L    | 209.2 ± 69.38 | 212.0 ± 60.64 | 146.8 ± 7.14 | 219.0 ± 46.85 | 66.0 ± 6.88 |
| AST IU/L    | 296.9 ± 53.02 | 279.6 ± 43.44 | 228.6 ± 10.88 | 238.8 ± 25.25 | 208.4 ± 20.78 |
| ALP IU/L    | 276.9 ± 39.06 | 246.1 ± 5.54 | 221.4 ± 29.71 | 207.2 ± 18.54 | 299.3 ± 39.60 |
| Total Protein g/dL | 6.20 ± 0.39 | 12.08 ± 3.37 | 8.0 ± 1.36 | 5.90 ± 1.33 | 8.52 ± 0.46 |
| Albumin mg/dL | 3.60 ± 0.19 | 4.58 ± 0.76 | 5.24 ± 1.37 | 6.62 ± 1.59 | 4.06 ± 0.25 |
| Glucose mg/dL | 115.7 ± 6.16 | 135.1 ± 7.95 | 92.22 ± 16.19 | 131.3 ± 19.92 | 114.9 ± 10.15 |
| Total bilirubin mg/dL | 0.24 ± 0.24 | 0.24 ± 0.02 | 0.26 ± 0.04 | 0.74 ± 0.31 | 0.26 ± 0.02 |
| Direct bilirubin mg/dL | 0.12 ± 0.02 | 0.10 ± 0.03 | 0.160 ± 0.04 | 0.14 ± 0.05 | 0.120 ± 0.02 |
| Urea mg/dL  | 37.43 ± 5.72 | 35.17 ± 3.32 | 33.83 ± 3.83 | 48.17 ± 4.30 | 54.67 ± 6.33 |
| Creatinine mg/dL | 0.64 ± 0.07 | 0.79 ± 0.31 | 2.18 ± 1.14 | 1.74 ± 0.91 | 0.84 ± 0.05 |
| Cholesterol mg/dL | 53.03 ± 7.22 | 57.13 ± 5.34 | 63.78 ± 2.80 | 58.57 ± 21.28 | 78.85 ± 6.40 |
| Triglycerides mg/dL | 52.57 ± 14.57 | 51.34 ± 10.46 | 50.11 ± 1.60 | 53.53 ± 6.99 | 68.72 ± 5.94** |
| HDL mg/dL    | 9.87 ± 0.78 | 19.37 ± 9.54 | 12.60 ± 3.15 | 14.56 ± 4.40 | 10.96 ± 0.55 |
| Phosphorous mg/dL | 17.32 ± 6.07 | 24.04 ± 6.85 | 22.38 ± 3.1 | 26.08 ± 11.58 | 21.34 ± 16.60 |

Female

| Unit        | Control | Asdamarin (mg/kg) |
|-------------|---------|-------------------|
|             |         |                   |     |      |               |
| ALT IU/L    | 74.40 ± 4.98 | 100.5 ± 15.44 | 101.4 ± 10.46 | 108.6 ± 16.59 | 52.2 ± 7.14 |
| AST IU/L    | 170.6 ± 7.69 | 180.4 ± 15.46 | 178.5 ± 17.91 | 189.0 ± 23.67 | 175.5 ± 9.74 |
| ALP IU/L    | 160.0 ± 17.89 | 190.3 ± 31.15 | 142.7 ± 6.46 | 184.6 ± 34.12 | 165.4 ± 18.7 |
| Total Protein g/dL | 13.90 ± 12.4 | 14.1 ± 1.56 | 11.48 ± 1.00 | 11.84 ± 1.59 | 10.58 ± 1.14 |
| Albumin mg/dL | 4.08 ± 0.08 | 3.86 ± 0.09 | 3.720 ± 0.31 | 3.82 ± 0.198 | 3.66 ± 0.19 |
| Glucose mg/dL | 107.7 ± 9.17 | 117.8 ± 22.54 | 121.1 ± 11.32 | 110.1 ± 34.12 | 109.9 ± 6.27 |
| Total bilirubin mg/dL | 0.28 ± 0.04 | 0.34 ± 0.14 | 0.36 ± 0.09 | 0.26 ± 0.07 | 0.32 ± 0.037 |
| Direct bilirubin mg/dL | 0.16 ± 0.02 | 0.18 ± 0.08 | 0.24 ± 0.05 | 0.14 ± 0.02 | 0.16 ± 0.02 |
| Urea mg/dL  | 123.2 ± 13.82 | 107.8 ± 17.75 | 150.7 ± 36.99 | 130.7 ± 12.54 | 51.49 ± 3.86 |
| Creatinine mg/dL | 0.43 ± 0.04 | 1.09 ± 0.66 | 1.83 ± 1.21 | 1.04 ± 0.17 | 0.69 ± 0.1 |
| Cholesterol mg/dL | 69.58 ± 8.39 | 55.86 ± 4.96 | 53.24 ± 6.20 | 63.03 ± 8.54 | 61.76 ± 3.76 |
| Triglycerides mg/dL | 65.15 ± 12.15 | 44.65 ± 13.84 | 53.12 ± 10.79 | 44.05 ± 23.35 | 101.7 ± 29.26 |
| HDL mg/dL    | 64.70 ± 5.65 | 60.44 ± 5.52 | 62.44 ± 6.70 | 68.13 ± 3.76 | 74.76 ± 3.92 |
| Calcium mg/dL | 9.41 ± 0.19 | 8.44 ± 0.42 | 9.54 ± 0.90 | 7.35 ± 2.65 | 9.33 ± 0.13 |
| Phosphorous mg/dL | 23.02 ± 2.88 | 14.90 ± 5.17 | 13.28 ± 5.31 | 22.70 ± 6.80 | 24.42 ± 4.2 |

Values are expressed as mean ± s.e.m. (n = 10 for each group). *p < 0.05 were considered significant using one-way Anova. **p < 0.01 Vs. control.

**Discussion**

We have investigated the efficacy of a combination of herbal extracts such as *F. asafoetida* and *S. marianum* (Asdamarin) in mitigating the delayed gastric emptying associated with functional dyspepsia, using phenol red method in rats. In accordance with Rome III criteria, FD is categorized based on the symptoms into post-prandial distress syndrome (PDS) and epigastric pain syndrome (EPS) [4]. Gastric emptying is the natural process of clearing the content of the stomach after food consumption, and transferring to the small
intestine [2]. PDS pathogenesis involves delay in gastric emptying and impaired gastric acclimatization [25]. Delayed gastric emptying and gastrointestinal motility are the main contributors to the gastrointestinal problems such as functional dyspepsia and nausea. Amelioration of gastrointestinal functions by mitigating the gastric emptying is an effective strategy to treat FD [25]. In the present study a 7-day pre-treatment with Asdamarin dose-dependently improved the gastric emptying rats. Gastric hypomotility involves dysfunction of serotonergic receptors 5-HT3/5-HT4 receptors [26]. It could be possible that the active constituents in Asdamarin modulate these receptors to exert its efficacy. We also found that Asdamarin significantly increased the intestinal transit in rats. Several prokinetic drugs of synthetic origin have similar mode of action [27]. However, the associated side effects of these medications cannot be ignored [28, 29]. In the light of these facts, the present study provide evidence on the efficacy of Asdamarin as a functional ingredient which could be explored in the treatment of FD.

We have further evaluated the toxicity of Asdamarin in rats. Single high dose (2000 mg kg$^{-1}$) administration of Asdamarin had no adverse effect on the rats after a 14-day observation. Sub-acute administration of Asdamarin did not induce any clinical signs of toxicity or mortality in the rats of either sex. There was no significant change in the food and water consumption by the rats throughout the study. Alterations in food and water consumption due to loss of appetite are often correlated to the decrement in body weight [30]. Furthermore, there was no significant change in the Asdamarin treated rats compared to the control group. Body weight changes are generally corroborated with the health status of an individual [31]. The data obtained from the present study clearly indicate that repeated oral consumption of Asdamarin does not have any adverse effect on the body metabolism. No significant changes were recorded in the relative organ weights of rats suggesting that Asdamarin had no effect on the normal growth. It was correlated well with the gross observation and the histopathology findings. There were no major haematological and biochemical changes in
rats of either sex administered with the test doses of Asdamarin.

**Conclusion**

Asdamarin is a unique herbal ingredient associating two well-known plants, together contributing to improvement in gastric emptying. The present study also provides preliminary evidence on the possible use of Asdamarin in treating the symptoms of FD such as delayed gastric emptying. No lethality or toxic signs were evident following acute and sub-acute administration of Asdamarin indicating the safety of the formulation.

**Abbreviations**

ALT: Alanine aminotransferase; ANOVA: Analysis of variance; AST: Aspartate aminotransferase; CPCSEA: Committee for the purpose of control and supervision of experiments on animals; EDTA: Ethylenediaminetetraacetic acid; EPS: Epigastric pain syndrome; FD: Functional dyspepsia; GIT: Gastrointestinal transit; H&E: Hematoxylin and eosin; HPLC: High performance liquid chromatography; MCV: Mean corpuscular volume; OECD: Organization for economic cooperation and development; PDS: Postprandial distress syndrome; SSRI: Serotonin re-uptake inhibitors

**Acknowledgements**

We thank Department of Preclinical Laboratory and Phytochemistry for the technical support.

**Authors’ contributions**

All authors have read and approved the final version of the manuscript. Conceptualization, investigation and writing, RI, SHV, DD and SK; animal experiment and statistical analysis, RI and SHV; review and editing, SHV, DD and SK; supervision, SHV and SK.

**Funding**

This study was funded by Vidya Herbs (P) Ltd. The study was performed at Vidya Herbs R&D Center. All the authors who have made substantial contribution in the design, experimentation and interpretation of data, manuscript preparation, are employees of Vidya Herbs (P) Ltd.

**Availability of data and materials**

The data sets used and/or analysed during the current study available from the corresponding author on reasonable request.

**Ethics approval and consent to participate**

The protocol contained in the present research has been approved by the Institutional Animal Ethics Committee (IAEC) of Vidya Herbs (P) Ltd. The animal studies were performed after due clearance from the IAEC (MHPL/PL/IAC/05/18) independently formed by CPCSEA (Committee for the purpose of control and supervision of experiments on animals, a statutory committee established under the Prevention of Cruelty to Animals Act, 1960 in India).

**Consent for publication**

Not applicable.

**Competing interests**

We have read and understood the BMC policy on declaration of interests and declare the following interests: All the authors are employees of Vidya Herbs (P) Ltd. that funded the study. The test formulation (Asdamarin) used...
in this study was provided by the Department of Quality control, Vidya Herbs (P) Ltd.

Author details
1Pretclinical Research Laboratory, R&D Center for Excellence, Vidya Herbs Pvt. Ltd, AnekalTaluk, Jigani Industrial Area, #14A, KIADB, Jigani I phase, Bangalore, Karnataka 560 105, India. 2Vidya Europe SAS, 7 avenue de Norvège, 91140 Villebon sur Yvette, France.

Received: 20 December 2018 Accepted: 25 June 2019

Published online: 05 July 2019

References
1. Kawachi M, Matsunaga Y, Tanaka T, Hori Y, Ito K, Nagahama K, et al. Acetamidomethylhydrochloride (Z-338) enhances gastric motility and emptying by inhibiting acetylcholinesterase activity in rats. Eur J Pharmocol. 2011;666:218–25.
2. Brook RA, Kleinman NL, Choung RS, Melkonian AK, Smeeding JE, Talley NJ. Functional dyspepsia impacts absenteeism and direct and indirect costs. Clin Gastroenterol Hepatol. 2010;8(6):498–503.
3. Aru P, Talley NJ, Ronkainen J, Storknab T, Vieth M, Johannsen SE, et al. Anxiety is associated with uninvestigated and functional dyspepsia (Rome III criteria) in a Swedish population-based study. Gastroenterol. 2009;137:94–100.
4. Choung RS, Locke GR, Schleck CD, Zinsmeister AR, Talley NJ. Do distinct dyspepsia subgroups exist in the community? A population-based study. Am J Gastroenterol. 2007;102:1893–9.
5. Khanne C, Fallah Huseini H, Abdi H, Mohtashami R, Nabati F, Kianbakht S. Efficacy of Mentha pulegium extract in the treatment of functional dyspepsia: a randomized double-blind placebo-controlled clinical trial. J Ethnopharmacol. 2017;206:267–73.
6. Raveendra KR, Jayachandra SV, Sushma KR, Allau JJ, Goudar KS, et al. An extract of Glyceria flava glabra (GutGard) alleviates symptoms of functional dyspepsia: a randomized, double-blind, placebo-controlled study. Evid Based Complement Alternat Med. 2012;9.
7. Karimi A, Majlesi M, Rafiean-Kopaei M. Herbal versus synthetic drugs; beliefs and facts. J Nephroheupharma. 2015;4(1):27–30.
8. Monkeimuller K, Malfertheiner P. Drug treatment of functional dyspepsia. World J Gastroenterol. 2006;12(17):2696–700.
9. Sehebkar A, Iranskahhi M. Biological activities of essential oils from the genus Ferula (Apiaceae). Asian Biomed. 2010;4:385–47.
10. Duan H, Takashi Y, Tori M, Takaoka S, Honda G, Ito M, et al. Polysulfide derivatives from Ferula foetida. J Nat Prod. 2002;65:1667–9.
11. Mahendra P, Bishft S. Ferula asafoetida: traditional uses and pharmacological activity. Pharmacogn Rev. 2012;6:141–6.
12. Takeoka G. Volatile constituents of Asafoetida. In: Takeoka GR, Guntert M, Engel K-H, editors. Aroma active compounds in foods. Washington, DC: American Chemical Society; 2001. p. 33–44.
13. Patle K, Sinivasan K. Influence of dietary spices and their active principles on pancreatic digestive enzymes in albino rats. Nahrung. 2000;44(1):42–6.
14. Gopi S, Amalraj A, Jude S, Varma K, Sheeraj TR, Hapaniuk JT, et al. Preparation, characterization and anti-colitis activity of curcumin-asafoetida complex encapsulated in turmeric nanofiber. Mater Sci Eng C Mater Biol Appl. 2017;81:20–31.
15. Vijayastelar I, Jyssy UI, Joseph A, Malaki B, Kuttan R, Krishnakumar IM. Beyond the flavor: a green formulation of Ferula asafoetida oleo-gum-resin with fenugreek dietary fibre and its gut health potential. Toxicol Rep. 2017;4:382–90.
16. Bagheri SM, Heizazian SH, Dashir RH. The relaxant effect of seed’s essential oil and oleo-gum-resin of Ferula Assa-foetida on isolated rat’s ileum. Am Med Sci Res. 2014;2(2):388–41.
17. Fatahi M, Farshad M, Fatemi-Hassanabad Z. Antispasmodic and hypotensive effects of Ferula asafoetida gum extract. J Ethnopharmacol. 2004;91:321–4.
18. Natural Medicines Comprehensive Database: professional version. Milk thistle monograph. Stockton (CA): Therapeutic Research Faculty; 2012.
19. Khazani K, Gorin Y, Caglioni RC, Abboud HE, Fanti P. The antioxidant sulfine prevents high glucose-induced oxidative stress and podocyte injury in vitro and in vivo. Am J Physiol Renal Physiol. 2013;305(5):F691–700.
20. Aghazadeh S, Amini R, Yazdanparast R, Ghaffari SH. Anti-apoptotic and anti-inflammatory effects of Silybum marianum in treatment of experimental steatohepatitis. Exp Toxicol Pathol. 2011;63(6):569–74.